Fetroja® (cefiderocol) – New drug approval
November 14, 2019 - The FDA announced the approval of Shionogi’s Fetroja (cefiderocol), in patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.
Top